secwatch.observer — SEC 8-K summary
======================================

Issuer:     TALPHERA, INC. (TLPH)
CIK:        0001427925
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001437749-24-016626
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Talphera reports Q1 2024 net loss $4.0M; NEPHRO study enrollment delayed, guidance revised
--------------------------------------------------------------------------------

- Net loss from continuing ops $4.0M vs income $0.1M in Q1 2023; basic EPS -$0.16.
- Cash and investments $18.6M as of March 31, 2024.
- NEPHRO CRRT study enrollment delayed; top-line data guidance (by Sept 30) to be revised.
- Dr. Shakil Aslam appointed Chief Development Officer effective May 20, 2024.
- Combined R&D and SG&A expenses decreased to $4.2M from $5.3M year-over-year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427925/000143774924016626/0001437749-24-016626-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427925/000143774924016626/acrx20240513_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-016626

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer